A US generics manufacturer that grew revenue more than 100% year over year. Debt-free, over 50% gross margins, trading at under 7x EBITDA, and led by a founder-CEO with more than a quarter of the company and hundreds of millions of his own net worth on the line.

The catalysts are what make it even more interesting: an outright sale of the company, at a moment when US-based manufacturing has rarely mattered more, or a potential uplisting to a national exchange that would unlock institutional capital.

50-plus pages of high-quality research. The full model live inside and in our private Dashboard. 👇

If you liked this piece, you will love this channel <3

Read us. Join us. Sleep well. ✨